We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-12.3%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$784M
AUM Growth
-$237M
Cap. Flow
-$75.7M
Cap. Flow %
-9.66%
Top 10 Hldgs %
46.1%
Holding
163
New
33
Increased
30
Reduced
43
Closed
36

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$37.3M
2
INCY icon
Incyte
INCY
+$11.2M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$8.68M
4
SHPG
Shire pic
SHPG
+$8.32M
5
BIIB icon
Biogen
BIIB
+$8.01M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$22.8M
2
GILD icon
Gilead Sciences
GILD
+$22.2M
3
PFE icon
Pfizer
PFE
+$10.1M
4
CXRX
Concordia International Corp. Common Stock
CXRX
+$9.03M
5
VRNT
Verint Systems
VRNT
+$8.47M

Sector Composition

Rank Sector Weight
1 Healthcare 55.74%
2 Industrials 4.06%
3 Utilities 2.54%
4 Technology 1.27%
5 Consumer Discretionary 0.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BITI
76
DELISTED
BIOTIE THERAPIES CORP SPONSORED ADR
BITI
$2.58M 0.33%
196,800
– –
CYTK icon
77
Cytokinetics
CYTK
$10.5B
$2.49M 0.32%
372,250
-50,000
-12% -$341K
MDLZ icon
78
Mondelez International
MDLZ
$79.5B
$2.49M 0.32%
+59,475
New +$2.56M
XLRN
79
DELISTED
Acceleron Pharma
XLRN
$2.49M 0.32%
100,000
– –
KERX
80
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$2.46M 0.31%
+700,000
New +$4.69M
DVAX
81
DELISTED
Dynavax Technologies
DVAX
$2.45M 0.31%
100,000
-50,000
-33% -$1.42M
ABEO icon
82
Abeona Therapeutics
ABEO
$366M
$2.43M 0.31%
+24,000
New +$3.19M
PTNR
83
DELISTED
Partner Communications
PTNR
$2.42M 0.31%
+617,951
New +$2.5M
QURE icon
84
uniQure
QURE
$3.03B
$2.35M 0.3%
115,000
– –
ELLO icon
85
Ellomay Capital Ltd
ELLO
$270M
$2.33M 0.3%
221,097
-25,600
-10% -$232K
SCYX icon
86
SCYNEXIS
SCYX
$48.1M
$2.28M 0.29%
3,913
– –
ATYR
87
aTyr Pharma
ATYR
$47.6M
$2.15M 0.27%
14,931
– –
SMMT icon
88
Summit Therapeutics
SMMT
$10.4B
$2.14M 0.27%
205,200
– –
CEMP
89
DELISTED
Cempra, Inc.
CEMP
$2.09M 0.27%
+75,000
New +$2.79M
IMDZ
90
DELISTED
Immune Design Corp.
IMDZ
$2.07M 0.26%
170,000
+30,000
+21% +$562K
PRTA icon
91
Prothena Corp
PRTA
$425M
$2.05M 0.26%
45,133
-70,000
-61% -$4.08M
AEGR
92
DELISTED
Aegerion Pharmaceuticals
AEGR
$2.04M 0.26%
+150,000
New +$2.67M
HALO icon
93
Halozyme
HALO
$9.79B
$2.02M 0.26%
150,000
– –
WAB icon
94
Wabtec
WAB
$49.1B
$2M 0.26%
22,735
+370
+2% +$35.3K
RLYP
95
DELISTED
RELYPSA INC COM
RLYP
$1.98M 0.25%
107,000
-25,000
-19% -$687K
EPZM
96
DELISTED
Epizyme, Inc
EPZM
$1.93M 0.25%
+150,000
New +$3.03M
SGEN
97
DELISTED
Seagen Inc. Common Stock
SGEN
$1.93M 0.25%
50,000
-90,000
-64% -$4.05M
TRIL
98
DELISTED
Trillium Therapeutics Inc.
TRIL
$1.92M 0.24%
147,000
– –
NVS icon
99
Novartis
NVS
$297B
$1.84M 0.23%
22,320
-89,280
-80% -$7.95M
SRPT icon
100
Sarepta Therapeutics
SRPT
$1.57B
$1.77M 0.23%
55,000
-95,000
-63% -$3.22M
2 3
4
5 6

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q3 2015 Portfolio in Review

As of Q3 2015, Sphera Funds Management held 163 positions worth $784M, down 23% from $1.02B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Sphera Funds Management withdrew a net $75.7M in Q3 2015, closing 36 positions and reducing 43 holdings. Its most notable exit was Merck, an estimated $22.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, up from 51% a quarter earlier, followed by Industrials and Utilities.

Against the trend, Sphera Funds Management opened a new position in Incyte worth $11M.

  • Sphera Funds Management's largest Q3 2015 buy was Incyte: 100,000 shares worth $11M.
  • Sphera Funds Management added most to Teva Pharmaceuticals in Q3 2015, an estimated $37.3M increase.
  • Sphera Funds Management's biggest Q3 2015 reduction was Gilead Sciences, cutting an estimated $22.2M.
  • Sphera Funds Management fully exited Merck in Q3 2015, selling an estimated $22.8M.
  • Sphera Funds Management's ten largest holdings make up 46% of its $784M portfolio in Q3 2015.
  • Sphera Funds Management opened 33 new positions and closed 36 in Q3 2015.
  • Sphera Funds Management's portfolio value fell 23% quarter-over-quarter to $784M.

Based on Sphera Funds Management's 13F filing for Q3 2015, filed 16 Nov 2015.